Dual functional liposomes carrying antioxidants against tau hyperphosphorylation and apoptosis of neurons

Kuo, Yung‐Chih; Lou, Yung-I; Rajesh, Rajendiran

doi:10.1080/1061186x.2020.1761819

Cited by 12 publications

(5 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kuo et al demonstrated apolipoprotein E-modified liposomes conjugated with phosphatidic acid as a carrier for rosmarinic acid and quercetin to infiltrate the BBB to block Aβ 1-42 -induced AD (Kuo et al, 2018). Likewise, attachment of specific ligand, targeted delivery by nanoparticles, and nanoemulsion through intranasal administration were used to rescue neurodegeneration (Fachel et al, 2020;Kuo et al, 2020;Long et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

Rosmarinus officinalis and Methylphenidate Exposure Improves Cognition and Depression and Regulates Anxiety-Like Behavior in AlCl3-Induced Mouse Model of Alzheimer’s Disease

2022

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurological illness that causes severe cognitive impairment. AD patients also experience at least one of the neuropsychiatric symptoms including apathy, depression, and anxiety during the course of their life. Acetylcholine esterase inhibitors are the available treatment options to alleviate cognitive deficits, whereas methylphenidate (MPH), a psychostimulant, is considered for the treatment of apathy in AD patients. Rosmarinus officinalis, a perennial herb, has been potentially known to have antioxidant and anti-inflammatory properties. The present study investigated the potential effects of MPH and R. officinalis in comparison with the standard drug, Donepezil, on cognition, anxiety, and depression in the AlCl3-induced mouse model of AD. The animals were divided into eight groups (n = 8, each). The results revealed that the MPH- and R. officinalis-treated groups significantly improved memory impairment, whereas R. officinalis substantially reduced depression and anxiety as compared with other treatment groups. MPH treatment induced an antidepressant effect and increased anxiety-like behavior. Moreover, the AlCl3 exposure led to the formation of amyloid beta (Aβ) plaques in mice hippocampus; however, none of the tested drugs caused a significant reduction in amyloid burden at the selected doses. The present study suggested the potential of R. officinalis to improve memory as well as neuropsychiatric symptoms in AD. Although R. officinalis improved cognitive abilities, it did not reduce the amyloid plaque burden, which indicates that the memory-enhancing effects of R. officinalis are due to some alternate mechanism that needs to be explored further.

show abstract

Section: Discussionmentioning

confidence: 99%

Rosmarinus officinalis and Methylphenidate Exposure Improves Cognition and Depression and Regulates Anxiety-Like Behavior in AlCl3-Induced Mouse Model of Alzheimer’s Disease

2022

View full text Add to dashboard Cite

show abstract

“…[ 63 ] Moreover, scientists developed quercetin‐ and rosmarinic acid‐loaded liposomes conjugated with phosphatidic acid and apolipoprotein E, showing effectively BBB penetration and neuronal recovery from Aβ‐induced neurotoxicity both in vivo and in vitro. [ 64 ] Here, for the first time, we demonstrated that using neurotransmitter‐derived nanoparticles efficiently delivered the anti‐aging agent SSK1 to the brain lesions of AD mice, at where the drug selectively induced senescent cell apoptosis and Aβ plaque clearance, in turn restored cognitive activity. Furthermore, SSK1‐NPs might also induce senescent cell apoptosis in muscles and thus improve the physiological function of aged mice.…”

Section: Resultsmentioning

confidence: 97%

SSK1‐Loaded Neurotransmitter‐Derived Nanoparticles for Alzheimer's Disease Therapy via Clearance of Senescent Cells

Ji,

Zhou,

Liang

et al. 2024

Small

View full text Add to dashboard Cite

Age is a significant contributor to the onset of AD. Senolysis has been recently demonstrated to ameliorate aging‐associated diseases that showing a great potential in AD therapy. However, due to the presence of BBB, the anti‐AD activity of senolytics are significantly diminished. SSK1 is a prodrug that can be activated by β‐gal, a lysosomal enzyme commonly upregulated in senescent cells, and thus selectively eliminates senescent cells. Furthermore, the level of β‐gal is significantly correlated with conventional AD genes from clinical sequencing data. SSK1‐loaded neurotransmitter ‐derived lipid nanoparticles are herein developed (SSK1‐NPs) that revealing good BBB penetration and bioavailability of in the body. At the brain lesion, SSK1‐NP treatment significantly reduces the expression of genes associated with senescence, induced senescent cells elimination, decreased amyloid‐beta accumulation, and eventually improve cognitive function of aged AD mice. SSK1‐NPs, a novel nanomedicine displaying potent anti‐AD activity and excellent safety profile, provides a promising strategy for AD therapy.

show abstract

“…For this reason, the development of pharmaceutical formulations is required to exploit the therapeutic potential of quercetin. Different strategies were evaluated for this purpose: (i) the cyclodextrin inclusion complex [ 161 ] and injectable solid dispersions [ 160 ] for increasing the water solubility and stability; (ii) different solid lipid nanoparticles [ 162 , 163 ]; (iii) liposomes conjugated with phosphatidic acid and targeted with apolipoprotein E [ 25 ]; (iv) exosomes targeted with a monoclonal antibodies [ 164 ]; (v) co-administration with α-tocopherol [ 146 ]; (vi) water-soluble conjugates with hyaluronic acid, targeted with a penetrating polypeptide [ 165 ]; (vii) quercetin-conjugated superparamagnetic iron oxide nanoparticles [ 166 , 167 , 168 , 169 ]; and quercetin-conjugated iron oxide –β-cyclodextrin nanoparticles [ 170 ] for improving the oral and/or brain bioavailability of quercetin.…”

Section: Innovative Formulations Designed To Enhance the Central Effe...mentioning

confidence: 99%

“…This review summarises the results of studies aiming to individuate innovative strategies to improve the efficacy of phytochemicals in the CNS through exploiting combination therapy with other drugs (co-administrations), or through their administration as prodrugs or conjugates. Particular attention has been paid to nanotechnology formulations supported by conjugation strategies with appropriate targeting molecules [ 15 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ]. The phytochemicals most evaluated in the reviewed studies are polyphenols, classified as non-flavonoids (gallic acid, ferulic acid, caffeic acid, curcumin and resveratrol) or flavonoids (baicalein, 7,8-dihydroxyflavone, epigallocatechin gallate and quercetin) [ 32 ], and the main components of essential oils (geraniol and cinnamaldehyde) [ 31 , 33 ].…”

Section: Introductionmentioning

confidence: 99%

Conjugation, Prodrug, and Co-Administration Strategies in Support of Nanotechnologies to Improve the Therapeutic Efficacy of Phytochemicals in the Central Nervous System

et al. 2023

View full text Add to dashboard Cite

Phytochemicals, produced as secondary plant metabolites, have shown interesting potential therapeutic activities against neurodegenerative diseases and cancer. Unfortunately, poor bioavailability and rapid metabolic processes compromise their therapeutic use, and several strategies are currently proposed for overcoming these issues. The present review summarises strategies for enhancing the central nervous system’s phytochemical efficacy. Particular attention has been paid to the use of phytochemicals in combination with other drugs (co-administrations) or administration of phytochemicals as prodrugs or conjugates, particularly when these approaches are supported by nanotechnologies exploiting conjugation strategies with appropriate targeting molecules. These aspects are described for polyphenols and essential oil components, which can improve their loading as prodrugs in nanocarriers, or be part of nanocarriers designed for targeted co-delivery to achieve synergistic anti-glioma or anti-neurodegenerative effects. The use of in vitro models, able to simulate the blood–brain barrier, neurodegeneration or glioma, and useful for optimizing innovative formulations before their in vivo administration via intravenous, oral, or nasal routes, is also summarised. Among the described compounds, quercetin, curcumin, resveratrol, ferulic acid, geraniol, and cinnamaldehyde can be efficaciously formulated to attain brain-targeting characteristics, and may therefore be therapeutically useful against glioma or neurodegenerative diseases.

show abstract

Dual functional liposomes carrying antioxidants against tau hyperphosphorylation and apoptosis of neurons

Cited by 12 publications

References 48 publications

Rosmarinus officinalis and Methylphenidate Exposure Improves Cognition and Depression and Regulates Anxiety-Like Behavior in AlCl3-Induced Mouse Model of Alzheimer’s Disease

Rosmarinus officinalis and Methylphenidate Exposure Improves Cognition and Depression and Regulates Anxiety-Like Behavior in AlCl3-Induced Mouse Model of Alzheimer’s Disease

SSK1‐Loaded Neurotransmitter‐Derived Nanoparticles for Alzheimer's Disease Therapy via Clearance of Senescent Cells

Conjugation, Prodrug, and Co-Administration Strategies in Support of Nanotechnologies to Improve the Therapeutic Efficacy of Phytochemicals in the Central Nervous System

Contact Info

Product

Resources

About